top of page

Testosterone therapy telehealth programs: how to plan lab testing and monitoring

1 day ago
5 min read
Illustration of testosterone therapy lab monitoring for telehealth: a laptop video visit with a stethoscope, a rack of blood specimen tubes, a calendar with a repeating cycle for scheduled follow-up testing, a trend chart and a morning sunrise, in navy, pink and white

A testosterone therapy (TRT) telehealth program needs labs at three points: two early-morning fasting total testosterone tests before diagnosis, a baseline panel that screens for reasons not to start, and scheduled monitoring of testosterone, hematocrit and, for many men, PSA. The Endocrine Society's guideline sets that rhythm, and your lab workflow has to support it.


This guide is for telehealth platforms and men's health programs that offer testosterone therapy or hormone consults. It covers what current guidance asks of the lab, where programs most often go wrong, and what to ask a lab partner. It is general information, not medical advice. Ordering clinicians decide which tests each patient needs.



Why lab planning matters more in virtual men's health


Testosterone care is lab-driven at every step. A video visit can capture symptoms, but the diagnosis, the decision to start, and every dose change depend on numbers.


Scrutiny is also rising. In a July 2026 statement, the Endocrine Society stressed that symptoms alone are not diagnostic, that there isn't enough evidence to support population-level testosterone screening in men without symptoms, and that non-standardized assays can make the same sample read "low" at one lab and "normal" at another. For a telehealth program, the quality of the lab work is part of the quality of the care.



What the guideline asks for before treatment


The Endocrine Society's clinical practice guideline on testosterone therapy in men with hypogonadism (published 2018) remains the society's current guideline, and its 2026 statement reaffirms it. Its diagnostic steps translate directly into lab orders.



Confirming low testosterone


  • Two morning fasting total testosterone tests. Testosterone varies through the day and from day to day, and food can suppress it. The guideline calls for measuring fasting morning total testosterone and repeating it to confirm. The 2026 statement notes a common clinical threshold near 300 ng/dL.

  • An accurate, standardized assay. The guideline recommends an assay certified by an accuracy-based program such as the CDC Hormone Standardization Program (HoSt). CDC certifies total testosterone assays that stay within ±6.4% mean bias of its reference method.

  • Free testosterone when it matters. When total testosterone sits near the lower limit of normal, or the patient has a condition that changes sex hormone-binding globulin (SHBG), such as obesity, the guideline recommends free testosterone by equilibrium dialysis or an accurate calculation from total testosterone, SHBG and albumin. It advises against direct analog free testosterone immunoassays.

  • Timing around illness. The guideline says not to test men who are acutely ill, recovering, or on short-term medications that suppress testosterone, such as opioids.



Finding the cause and screening for reasons not to start


  • LH and FSH to tell primary (testicular) from secondary (pituitary or hypothalamic) hypogonadism. Some results, such as very low testosterone with low LH, may need prolactin testing and further workup.

  • Hematocrit. An elevated baseline hematocrit is one of the guideline's reasons not to start therapy without further evaluation.

  • PSA, when the patient chooses prostate monitoring. The guideline suggests shared decision-making about prostate monitoring for men 55 to 69, and for men 40 to 69 at higher risk. It lists a PSA above 4 ng/mL, or above 3 ng/mL in higher-risk men, as a reason for urological evaluation before starting.

  • Fertility plans. The guideline recommends against starting testosterone in men planning fertility in the near term, so intake should ask about it before the first prescription.



What monitoring looks like once a patient starts


The guideline's monitoring plan, summarized in this NIH Endotext table, sets a predictable schedule your lab ordering can be built around:


  • Testosterone at 3 to 6 months, aiming for the mid-normal range. The timing of the draw depends on the formulation. For testosterone enanthate or cypionate injections, it's measured midway between injections. For gels, it's measured 2 to 8 hours after application once the patient has been on treatment for at least a week.

  • Hematocrit at baseline, 3 to 6 months, then yearly. If hematocrit rises above 54%, the guideline says to stop therapy until it falls and to evaluate for causes such as sleep apnea.

  • PSA at 3 to 12 months, then per screening guidance, for men who chose prostate monitoring. A PSA rise of more than 1.4 ng/mL in the first 12 months, or a confirmed PSA above 4 ng/mL, should prompt a urology referral.

  • Clinical review at 3 to 12 months, then yearly, to check symptoms and side effects.


Blood pressure is now part of the picture too. In February 2025 the FDA required class-wide labeling changes for testosterone products, adding a warning about increased blood pressure and the results of the TRAVERSE trial. Blood pressure isn't a lab test, but your visit template should prompt for it alongside the lab review.



Where TRT lab workflows break down


Most problems come from logistics, not test menus:


  • Wrong collection timing. A random afternoon sample, or a trough drawn at the peak, can push a clinician toward the wrong decision. Build timing rules into the order and the patient instructions.

  • One test instead of two. Programs that diagnose on a single value skip the guideline's confirmation step.

  • Switching labs mid-program. Different assays and reference ranges make trends hard to read. Keep each patient's testing with one lab when you can.

  • Missed follow-up panels. Hematocrit and PSA checks are easy to skip when the patient feels fine. Automate reminders and re-ship kits on schedule.

  • No plan for flagged results. Decide in advance who reviews a hematocrit above 54% or a PSA jump, and how fast.



Questions to ask a lab partner


  1. Is the total testosterone assay certified by the CDC HoSt program, and can you share documentation?

  2. How is free testosterone measured: equilibrium dialysis, calculated, or direct immunoassay?

  3. Which hormone and safety tests are validated for at-home collection, and which need a venous draw?

  4. How are collection time and dose timing recorded with the specimen?

  5. How do critical or flagged results reach our clinicians, and how quickly?

  6. Can kits be re-shipped automatically on a monitoring schedule?

  7. Which states can you serve, and what licenses do you hold?

  8. Do results flow into our platform by API or EMR, or only as PDFs?


If your platform is still deciding how kits and results should flow, our guide to telehealth consultations with home lab kits walks through the workflow from order to results review.



Planning notes


  • Keep diagnosis and prescribing with clinicians. The lab runs what is ordered. Who qualifies and how to dose belong to your clinical team.

  • Write timing into the order. Morning, fasting and dose-relative timing should be part of the order set, not a footnote.

  • Track completion. Measure how many patients finish their 3 to 6 month and annual panels, not just how many start.


IHDLab is a CLIA-certified lab licensed in California, New York and Maryland that works with telehealth platforms on hormone and men's health lab testing, including white-label test kits. If you're mapping a TRT lab workflow, our team is happy to talk it through.

bottom of page